Journal
CANCER
Volume 122, Issue 3, Pages 367-377Publisher
WILEY
DOI: 10.1002/cncr.29769
Keywords
checkpoint inhibitors; hepatocellular carcinoma; immune evasion; immunotherapy
Categories
Funding
- Medimmune
- Bristol-Myers Squibb
- Merck
- SillaJen
- AstraZeneca
Ask authors/readers for more resources
Advanced hepatocellular carcinoma (HCC) carries a dismal prognosis and the current treatment is limited to sorafenib, an agent with modest benefit. Preclinical data have indicated that several immunologic mechanisms are at play to promote HCC development and growth while impairing effective antitumor immune surveillance. Several novel approaches geared toward manipulating the immune response to HCC have suggested a therapeutic benefit in early-stage clinical trials, indicating a real potential to augment tumor-specific immunity and improve outcomes in patients with this disease. In the current study, the authors reviewed the barriers to an effective immune response against HCC and contemporary clinical investigations that may be primed to alter the natural history of HCC. Cancer 2016;122:367-377. (c) 2015 American Cancer Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available